InsiderDB
Sign inStart free trial

Bristol-Myers Squibb Company (BMY)

Healthcare · Drug Manufacturers - General

26 members of Congress have disclosed 84 trades in Bristol-Myers Squibb Company (BMY) since 2014: 33 buys and 51 sales. The most recent was disclosed on Nov 5, 2026. 3 trades were made by members of a committee that oversees Bristol-Myers Squibb Company's industry.

Trades disclosed
84
Members trading
26
Buys / sells
33 / 51
Reported value
$951K–$3.1M

Keep following the company.

Subscribers get new congressional filings and notable insider purchases for companies they follow. Coverage varies by company.

Follow BMY

What else is happening at BMY

All research →

Company filings and public records connected to this stock, ordered by when they became public or were first observed.

  1. BMYFinancial report·SEC EDGAR

    BMY: 10-Q financial filing

    Filed 10-Q for an event or period dated 2026-09-30. Read the company report for its disclosures.

    Public: Oct 29, 2026, 11:16 AM EDTEvent / period: Sep 30, 2026Original source ↗

    1 congressional household disclosed purchases in the past 90 days. See the trades

  2. BMYCompany announcement·SEC EDGAR

    BMY: Financial results · Company disclosure

    Filed 8-K for an event or period dated 2026-10-29. Financial results; Company disclosure.

    Public: Oct 29, 2026, 7:05 AM EDTEvent / period: Oct 29, 2026Original source ↗

    1 congressional household disclosed purchases in the past 90 days. See the trades

  3. BMYLobbying report·Lobbying disclosures

    BMY: third_quarter 2026 lobbying report

    Access to prescription drugs. Policies related to 340B. Drug Pricing reform/implementation. Food is Medicine initiatives. Issues related to the budget and appropriations process

    Public: Oct 20, 2026, 11:15 PM EDTOriginal source ↗

    1 congressional household disclosed purchases in the past 90 days. See the trades

  4. BMYLobbying report·Lobbying disclosures

    BMY: third_quarter 2026 lobbying report

    Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. Issues related to the 340B program. Issues related to FDA regulation of pharmaceuticals.

    Public: Oct 20, 2026, 5:39 PM EDTOriginal source ↗

    1 congressional household disclosed purchases in the past 90 days. See the trades

  5. BMYLobbying report·Lobbying disclosures

    BMY: third_quarter 2026 lobbying report

    Issues related to biosimilars reimbursement, supply chain and Medicare/Medicaid payment reform. Issues related to biosimilars reimbursement, supply chain and Medicare/Medicaid payment reform.

    Public: Oct 20, 2026, 5:04 PM EDTOriginal source ↗

    1 congressional household disclosed purchases in the past 90 days. See the trades

Committee overlaps

Trades by members of a committee that oversees Bristol-Myers Squibb Company's industry. An overlap is a fact about the trade, not evidence of wrongdoing.

Who traded BMY

All trades

From periodic transaction reports filed under the STOCK Act. Amounts are the ranges members report, and trades can be disclosed up to 45 days after they happen. Nothing here is investment advice.